Related Experiment Video
Updated: Sep 5, 2025
Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation
Published on: August 8, 2025
IL-6 as a marker for NMOSD disease activity
Adi Haramati1, Ariel Rechtman2, Omri Zveik2
1Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center, Ein-Kerem, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Interleukin-6 (IL-6) serum levels are elevated during relapses in neuromyelitis optica spectrum disorder (NMOSD) patients. Increased IL-6 correlates with relapse severity and brain atrophy, suggesting its potential as a biomarker for NMOSD activity.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
- Neurology
Background:
- Neuromyelitis optica spectrum disorder (NMOSD) lacks validated soluble markers for disease activity and progression.
- Accurate monitoring of NMOSD is crucial for effective treatment and management.
Purpose of the Study:
- To investigate the potential of serum interleukin-6 (IL-6) as a biomarker for disease activity in NMOSD.
- To correlate longitudinal IL-6 levels with clinical relapse activity and brain volume changes in NMOSD patients.
Main Methods:
- Analysis of serum IL-6 levels in 26 NMOSD patients during both relapse and remission phases.
- Correlation of IL-6 levels with relapse severity and brain atrophy measurements.
Main Results:
- Significantly elevated IL-6 serum levels were observed in NMOSD patients during relapse compared to remission.
- Higher IL-6 levels were found to correlate with increased relapse severity and brain atrophy.
Conclusions:
- Serum IL-6 levels show promise as a potential biomarker for monitoring disease activity in NMOSD.
- IL-6 may play a role in NMOSD pathogenesis, particularly during relapses and contributing to neurodegeneration.
More Related Videos
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024